On November 11, Revolution Medicines, Inc. fell 4.13% in Regular Trading, trading at $184.891 per share, with turnover of $68.6961 million.
The clearest catalyst in recent market coverage is continued post-earnings valuation digestion following the company’s third-quarter report and a wave of analyst target-price increases.
Background shows Revolution Medicines, Inc. reported quarterly EPS of $(1.90), better than the $(2.42) consensus estimate, while revenue was $197.559 million versus a much lower market estimate that was flagged as not fully comparable. After the report, several firms raised targets, including RBC to $321, Evercore to $340, and JP Morgan to $289, reflecting confidence in the commercial outlook for Rasonque after its approval. Even so, recent coverage indicated that earlier optimism had already been substantially priced in, leaving the shares under pressure as investors reassessed valuation.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments